- Details
- Oliver Sartor joins Alicia Morgans and discusses the evolving landscape of BiTE ® technology applied to prostate cancer therapy. BiTE is a bispecific T-cell engaging antibody that binds on PSMA and CD3 on the T cells to activate the T cells. Bispecific T-cell engagers are a novel approach to tumor immunotherapy. They discuss the current clinical trials landscape and what is maybe on the horizon fo...
|
- Details
- In this UroToday discussion, Daniel Petrylak joins Tom Keane highlighting the ESMO 2021 data on CheckMate 9KD cohort A2. This was the final analysis of nivolumab and rucaparib for chemotherapy- naïve metastatic castration-resistant prostate cancer. Biographies: Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology; Co-Leader, Cancer Signaling Networks, Yale Cancer Center,...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the VISION trial, evaluating new patient-reported data. This patient-reported health-related quality of life data was presented at ESMO 2021. They discuss the VISION trial design, primary trial endpoints, and the importance of preserving good patient quality of life during advanced prostate cancer treatment. Biographies: Karim Fizazi, MD, Ph.D., is a medical...
|
- Details
- Fred Saad joins Alicia Morgans highlighting the efficacy of olaparib versus either abiraterone or enzalutamide, given a potential difference in the efficacy of NHA sequencing that he presented during a podium presentation at the American Urologic Association (AUA) Annual Meeting. The PROfound trial provided a rationale for United States Federal Drug Administration (FDA) approval of olaparib among...
|
- Details
- In this conversation Tanya Dorff and Alicia Morgans discuss the guidance coming from the NCCN on the use of radium-223 in the metastatic castration-resistant prostate cancer setting, including choosing the right patient for this drug, factors to consider, and the timing of this therapy. As lines of therapy become more complicated with many castration-resistant drugs moving to the hormone-sensitive...
|
- Details
- Alicia Morgans, MD, MPH, is joined by Michael Morris, MD, to discuss the phase III VISION trial results and the practice-changing implications when lutetium-177-PSMA-617 is FDA approved. The VISION trial evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined standard of care with...
|
- Details
- In this UroToday discussion, Thomas Keane is joined by Robert Bruce Montgomery to discuss his recent publication, entitled, “Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.” The conversation kicks off with Dr. Montgomery’s “bottom line” for his study, which was to make it easier for oncology providers to find men who can be...
|
- Details
- In this UroToday discussion between Charles Ryan and Mark Markowski, they focus on Dr Markowski’s recent study, entitled COMAT-CRPC. The COMBAT-CRPC study is a study with bipolar androgen therapy and nivolumab, which was conducted through the Prostate Cancer Clinical Trials Consortium. Dr. Markowski begins by discussing the criteria for patient eligibility, which was quite broad, which was to be a...
|
- Details
- The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D. In...
|
- Details
- Emmanuel Antonarakis joins Charles Ryan highlighting the first randomized study to assess high-dose testosterone as a treatment for metastatic castration-resistant prostate cancer (mCRPC). TRANSFORMER (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance) was led by Dr. Samuel R. Denmeade at Johns Hopkins School of Medicine – Sidney Kim...
|
